Zimbabwe has declined a significant American health deal valued at $367m (£272m) over five years due to the United States' insistence on sensitive data.
This move came to light after a government memo from December was disclosed, revealing that Head of State Emmerson Mnangagwa felt the agreement was "lopsided".
An official spokesperson has since clarified that the United States was seeking biological samples for research and commercial gain while refused to guarantee the resulting advantages from any future vaccines.
"We are forced to start the challenging and unfortunate task of ending our support in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont in a statement.
Her embassy indicated the United States had donated more than $1.9bn for health programmes to Zimbabwe during the past two decades.
A physicians' group in Zimbabwe has appealed for further talks to reach a deal agreeable to both sides so the country's critical HIV programme can be sustained.
Wider Background
This development follows a comparable case in Kenya, where a high court halted a related deal with the US after legal challenges were filed about the security of Kenyans' health data.
Since resuming office last year, US President Donald Trump has slashed foreign aid and shut down the key foreign aid agency.
The agency had overseen assistance for the American government, but Trump stated its expenditure was "inefficient" and his administration was pursuing government-to-government agreements to boost transparency and responsibility.
Based on reports, 16 nations in Africa have so far agreed to these new health pacts, representing more than $18.3bn in new funding.
Details of the Declined Agreement
The money for Zimbabwe would have gone towards "HIV/Aids treatment and prevention, tuberculosis, malaria, maternal and child health, and preparing for epidemics".
"We are confident this partnership might have yielded extraordinary advantages for Zimbabwean communities, particularly the 1.2 million men, women and children presently receiving antiretroviral therapy through US-supported initiatives," the Ambassador added.
However, government spokesperson Nick Mangwana argued the proposed deal was "unequal".
"Our nation was requested to provide its genetic material and health information indefinitely, without any equivalent guarantee of access to any medical innovations – like vaccines, diagnostics, or treatments – that could be developed from that provided information," he stated.
"In essence, our nation would provide the raw materials for medical research without any certainty that the final treatments would be accessible to our population if a future health crisis arise."
Sovereignty and Global Health
Mangwana further noted that the US's withdrawal from the World Health Organization (WHO) and its pursuit of bilateral deals were disrupting structures previously set up through the global health agency.
Mangwana gave as an example its Pandemic Benefit-Sharing framework created to deal with future pandemics.
"This system is designed to guarantee that when a nation provides its information, the resulting advantages – such as vaccines and treatments – are distributed fairly, not commercialised exclusively by those with the funds to develop them."
Zimbabwe's reservations regarding the US deal "are not meant as anti-American sentiment," Mangwana stressed.
"We encourage continued dialogue with our American counterparts on how future co-operation might be designed in a manner that respects the sovereignty and interests of each country."
Medical Community Response
The Zimbabwe College of Public Health Physicians (ZCPHP) stated it acknowledged the official position, but suggested that negotiations need to persist considering much of the country's HIV programmes depended on external financing.
"If technical issues exist, such as those relating to information security or implementation frameworks, these can often be resolved through detailed discussion and negotiated safeguards," the group said.
This impasse highlights the continuing debate between accepting vital international aid and safeguarding local interests in an ever more data-driven world.